MedTrace Logo

Low Dose Ketamine Infusion for the Treatment of Resistant Depression

NCT04283058 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-05-01

No results posted yet for this study

Summary

The purpose of this investigator-initiated observational study is to examine how low Ketamine infusion treatments impact antidepressant and anti-suicidal effects for refractory and non-refractory depression.

Conditions

Interventions

DRUG

Ketamine

d. Ketamine 0.5mg/kg\* dose IV in 50 mL NS will be infused at a set non-titratable rate over 40 minutes or Ketamine 1mg/kg\* dose IV in 50 mL NS will be infused at a set rate non-titratable over 90 minutes. The dose that the subject will receive will be determined by the Intensive Care Unit Attending based on patient symptoms. Ketamine administered at these doses may result in the following adverse reactions such as excessive sedation or drowsiness, or unpleasant hallucinations, agitation or dysphoric reaction, nausea or increased oral secretions.

Sponsors & Collaborators

  • Sarah Capalla

    collaborator UNKNOWN

  • Ebony HIllery

    collaborator UNKNOWN

  • Kaushik Mukherjee

    collaborator UNKNOWN

  • Timothy Lee

    collaborator UNKNOWN

  • Loma Linda University

    lead OTHER

Principal Investigators

  • Patricia Radovich, PhD · Loma Linda University Medical Center

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-29
Primary Completion
2020-12-29
Completion
2020-12-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04283058 on ClinicalTrials.gov